Latest news and press releases about TransCode Therapeutics, Inc. (RNAZ): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers.
Price
| Price | $1.68 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.01 |
| EV / EBITDA | 0.13 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -58.08% |
| Return on Invested Capital | -23.73% |
| Return on Assets | -28.33% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · APRE · APVO · BOLT · GLTO · HCWB · INAB
Explore sector: Healthcare · Biotechnology
More sections of RNAZ: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks